Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 5-ismn
2. 5-ismn Durules
3. Elantan
4. Imdur
5. Ismo
6. Isosorbide-5-mononitrate
7. Isosorbide-5-nitrate
8. Monizid
9. Mono Mac 50d
10. Monocinque
11. Monoket
12. Mononit
13. Olicard 40
14. Olicard-retard
1. Isosorbide 5-mononitrate
2. 16051-77-7
3. Imdur
4. Corangin
5. Monosorbitrate
6. Monoket
7. Elantan
8. Mononit
9. Isosorbide-5-mononitrate
10. Isosorbide 5-nitrate
11. Ismn
12. Ismo
13. Monolong
14. Monopront
15. Monosordil
16. Nitramin
17. Orasorbil
18. Promocard
19. Sigacora
20. Sorbimon
21. Turimonit
22. Vasdilat
23. Duride
24. Imtrate
25. Ismexin
26. Medocor
27. Monicor
28. Olicard
29. Pertil
30. Uniket
31. Ismox
32. Monodur Durules
33. Mono Corax
34. Monisid
35. Monocord
36. Isosorbidi Mononitras [latin]
37. Isosorbidi Mononitras
38. Mononitrate D'isosorbide [french]
39. Is 5-mn
40. Mononitrate D'isosorbide
41. Mononitrato De Isosorbida [spanish]
42. 1,4:3,6-dianhydro-d-glucitol 5-nitrate
43. Mononitrato De Isosorbida
44. Iso-5-mononitrate
45. Ahr-4698
46. Is-5-mn
47. D-glucitol, 1,4:3,6-dianhydro-, 5-nitrate
48. Is-5mn
49. 1,4:3,6-dianhydro-5-o-nitro-d-erythro-hexitol
50. Monizid
51. Bm 22.145
52. Bm-22-145
53. Vasotrate
54. Epicordin
55. Monoclair
56. Monotrate
57. Olicardin
58. Percorina
59. Edistol
60. Etimonis
61. Isomonat
62. Isomonit
63. Multitab
64. Titarane
65. Conpin
66. Imazin
67. Imodur
68. Isomon
69. Iturol
70. Monis
71. Nitex
72. Plodin
73. Ihd
74. Monosigma
75. Elantan Retard
76. Mono-sanorania
77. Monoket Retard
78. Nsc-758619
79. Elantan Long
80. Imdur Durules
81. Corangin Sr
82. Mono Mack
83. Mono-mack
84. Conpin Retardkaps
85. Diluted Isosorbide Mononitrate
86. Fem-mono
87. Ismn Lannacher
88. Monoket Od
89. Ismn Apogepha
90. Ismn Heumann
91. Ismn Basics
92. Pentacard 20
93. [(3s,3ar,6r,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] Nitrate
94. 1,4:3,6-dianhydro-5-o-nitro-d-glucitol
95. Mono Corax Retard
96. Chebi:6062
97. Ismn Hexal
98. Ismn Stada
99. Monocord 20
100. Monocord 40
101. Monolong 40
102. Monolong 60
103. Ismn Atid
104. Mononit 20
105. Mononit 40
106. Isopen-20
107. Monocord 50 Sr
108. Mononit Retard 50
109. 5-ismn
110. (3r,3as,6s,6ar)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl Nitrate
111. Imdur 60
112. Ismn Abz
113. Lx1oh63030
114. Monit 20
115. Ismn Al
116. Ismo-20
117. Isosorbide-5-nitrate
118. Monocedocard
119. Bm-22145
120. Is 5mn
121. Monosorb
122. Bm-22.145
123. (3r,3as,6s,6ar)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yl Nitrate
124. Bm 22.145is 5-mnahr-4698
125. Glucitol, 1,4:3,6-dianhydro-, 5-nitrate, D-
126. Monomax
127. Ahr 4698
128. Monosorb Xl 60
129. Ccris 1911
130. Imdur (tn)
131. Isosorbide Mononitrate (isosorbide 5-nitrate)
132. Ismo (tn)
133. Bm 22-145
134. Sr-05000001872
135. Einecs 240-197-2
136. Un3251
137. Brn 5851319
138. Leicester
139. Unii-lx1oh63030
140. Ncgc00159334-02
141. Isorbide Mononitrate
142. Mfcd00143462
143. Isosorbide-mononitrate
144. Isosobide-5-mononitrate
145. 5-isosorbide Mononitrate
146. Dsstox_cid_3176
147. Isosorbide Mononitrate,(s)
148. Chembl1311
149. Dsstox_rid_76905
150. Dsstox_gsid_23176
151. Isosorbide Mononitrate [usan:usp:inn:ban:jan]
152. Schembl26781
153. Gtpl7052
154. Dtxsid9023176
155. Niosh/lz4385560
156. Hms2093k07
157. Hms3715i08
158. Pharmakon1600-01503807
159. Hy-b0642
160. Zinc1849548
161. Isosorbide Mononitrate [inn]
162. Isosorbide Mononitrate [jan]
163. Tox21_111581
164. Isosorbide Mononitrate [usan]
165. Nsc758619
166. S4633
167. Isosorbide Mononitrate [vandf]
168. Akos005110986
169. Isosorbide Mononitrate [mart.]
170. Ac-8830
171. Ccg-213200
172. Cs-3495
173. Db01020
174. Isosorbide Mononitrate [who-dd]
175. Nsc 758619
176. Isosorbide Mononitrate (jp17/usp/inn)
177. Ncgc00167981-01
178. Ncgc00167981-03
179. D-1,4:3,6-dianhydroglucitol 5-nitrate
180. 1,4:3,6-dianhydrosorbitol 5-mononitrate
181. Sbi-0206724.p001
182. Cas-16051-77-7
183. Isosorbide Mononitrate [orange Book]
184. Bb 0261072
185. I0403
186. Isosorbide Dinitrate Isosorbide-5-mononitrate
187. Isosorbide Mononitrate [usp Impurity]
188. Lz43855600
189. C07714
190. D00630
191. Diluted Isosorbide Mononitrate [usp-rs]
192. W15583
193. Ab01563284_01
194. Q423401
195. Sr-05000001872-1
196. Sr-05000001872-2
197. W-107977
198. Brd-k82225283-001-01-5
199. Diluted Isosorbide Mononitrate [usp Monograph]
200. Isosobide-5-mononitrate [un3251] [flammable Solid]
201. Isosorbide Mononitrate 1.0 Mg/ml In Dimethyl Sulfoxide
202. Isosorbide Dinitrate Isosorbide-5-mononitrate [mi]
203. Isosorbide Dinitrate, Diluted Impurity C [ep Impurity]
204. [(3r,3as,6s,6ar)-6-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[2,3-d]furan-3-yl] Nitrate
Molecular Weight | 191.14 g/mol |
---|---|
Molecular Formula | C6H9NO6 |
XLogP3 | -0.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 1 |
Exact Mass | 191.04298701 g/mol |
Monoisotopic Mass | 191.04298701 g/mol |
Topological Polar Surface Area | 93.7 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 216 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Isosorbide mononitrate |
PubMed Health | Isosorbide Mononitrate (By mouth) |
Drug Classes | Antianginal, Coronary Vasodilator |
Drug Label | Isosorbide mononitrate (ISMN), an organic nitrate and the major biologically active metabolite of isosorbide dinitrate (ISDN), is a vasodilator with effects on both arteries and veins.Each tablet, for oral administration, contains either 30 mg, 60 mg... |
Active Ingredient | Isosorbide mononitrate |
Dosage Form | Tablet, extended release; Tablet |
Route | Oral |
Strength | 30mg; 120mg; 60mg; 10mg; 20mg |
Market Status | Prescription |
Company | Vintage Pharms; Ani Pharms; Torrent Pharms; Hikma Pharms; Dexcel; Nesher Pharms; Kremers Urban Pharms; Actavis Elizabeth |
2 of 4 | |
---|---|
Drug Name | Monoket |
PubMed Health | Isosorbide Mononitrate (By mouth) |
Drug Classes | Antianginal, Coronary Vasodilator |
Drug Label | monoket, an organic nitrate, is a vasodilator with effects on both arteries and veins. The empirical formula is C6H9NO6 and the molecular weight is 191.14. The chemical name for monoket is 1,4:3,6-Dianhydro-D-glucitol 5-nitrate and the compound h... |
Active Ingredient | Isosorbide mononitrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Kremers Urban Pharms |
3 of 4 | |
---|---|
Drug Name | Isosorbide mononitrate |
PubMed Health | Isosorbide Mononitrate (By mouth) |
Drug Classes | Antianginal, Coronary Vasodilator |
Drug Label | Isosorbide mononitrate (ISMN), an organic nitrate and the major biologically active metabolite of isosorbide dinitrate (ISDN), is a vasodilator with effects on both arteries and veins.Each tablet, for oral administration, contains either 30 mg, 60 mg... |
Active Ingredient | Isosorbide mononitrate |
Dosage Form | Tablet, extended release; Tablet |
Route | Oral |
Strength | 30mg; 120mg; 60mg; 10mg; 20mg |
Market Status | Prescription |
Company | Vintage Pharms; Ani Pharms; Torrent Pharms; Hikma Pharms; Dexcel; Nesher Pharms; Kremers Urban Pharms; Actavis Elizabeth |
4 of 4 | |
---|---|
Drug Name | Monoket |
PubMed Health | Isosorbide Mononitrate (By mouth) |
Drug Classes | Antianginal, Coronary Vasodilator |
Drug Label | monoket, an organic nitrate, is a vasodilator with effects on both arteries and veins. The empirical formula is C6H9NO6 and the molecular weight is 191.14. The chemical name for monoket is 1,4:3,6-Dianhydro-D-glucitol 5-nitrate and the compound h... |
Active Ingredient | Isosorbide mononitrate |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Kremers Urban Pharms |
Isosorbide mononitrate is indicated for the prevention and management of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid to be useful in aborting an acute anginal episode.
FDA Label
Isosorbide mononitrate is an anti-anginal agent and vasodilator that relaxes vascular smooth muscle to prevent and manage angina pectoris. The pharmacological action is mediated by the active metabolite, [nitric oxide], which is released when isosorbide mononitrate is metabolized. Nitric oxide works on both arteries and veins, but predominantly veins: by relaxing veins and reducing the central venous pressure, nitric oxide causes venous pooling and a decrease in the venous return to the heart, thus decreasing cardiac preload. In healthy subjects, the stroke volume is decreased and venous pooling can occur in the standing posture, leading to postural hypotension and dizziness. At therapeutic doses of isosorbide mononitrate, nitric oxide has a bigger effect on larger muscular arteries over small resistance arteries. Arterial relaxation leads to reduced systemic vascular resistance and systolic blood (aortic) pressure, decreasing to decreased cardiac afterload. The direct dilator effect on coronary arteries opposes the coronary artery spasm in variant angina or angina pectoris. At larger doses, nitric oxide causes the resistance arteries and arterioles to dilate, reducing arterial pressure via coronary vasodilatation. This leads to increased coronary blood flow. Reduced cardiac preload and afterload caused by nitric oxide causes a reduction in myocardial oxygen consumption; decreased myocardial oxygen demand, along with increased coronary blood flow, leads to an increased in the oxygen content of coronary sinus blood and the relief from ischemia. The end effect of isosorbide mononitrate include decreased cardiac oxygen consumption, redistribution coronary flow toward ischemic areas via collaterals, and the relief of coronary spasms. Nitric oxide can also increase the rate of relaxation of cardiac muscles, which is an effect outside of vascular smooth muscles. Organic nitrates can also relax other types of smooth muscles, including esophageal and biliary smooth muscle. The anti-anginal activity of isosorbide mononitrate was observed about 1 hour after dosing, and the peak effect was achieved from 1-4 hours after dosing. The duration of anti-anginal action of at least 12 hours was observed with an asymmetrical dosing regimen.
Nitric Oxide Donors
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) (See all compounds classified as Nitric Oxide Donors.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
C - Cardiovascular system
C01 - Cardiac therapy
C01D - Vasodilators used in cardiac diseases
C01DA - Organic nitrates
C01DA14 - Isosorbide mononitrate
Absorption
Upon oral administration, isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. Isosorbide mononitrate has a dose-linear kinetics and the absolute bioavailability is nearly 100%. The Cmax is reached within 30 to 60 minutes following administration.
Route of Elimination
In a human radio-labelled drug study, about 93% of the total dose was excreted in the urine within 48 hours. Following oral administration of 20 mg, only 2% of isosorbide mononitrate was excreted unchanged in the urine within 24 hours. Among the excreted dose, nearly half of the dose was found de-nitrated in urine as isosorbide and sorbitol: approximately 30% is excreted as isosorbide and about 17% is the 2-glucuronide of mononitrate. These metabolites were not vasoactive or pharmacologically active. Renal excretion was complete after 5 days, and fecal excretion accounted for only 1% of drug elimination.
Volume of Distribution
The volume of distribution is approximately 0.6 L/kg, which is approximately the volume of total body water.
Clearance
The total body clearance is 115-120 mL/min.
Isosorbide mononitrate is not subject to first pass metabolism in human liver. Detectable metabolites include isosorbide, sorbitol, and 2-glucuronide of mononitrate, which are pharmacologically inactive.
The elimination half-life of isosorbide mononitrate is about 5 hours. The elimination half-life of its metabolites, isosorbide and 2-glucuronide of mononitrate, are 8 hours and 6 hours, respectively.
Isosorbide mononitrate acts as a prodrug for nitric oxide (NO), which is a potent vasodilator gas that is released when the drug is metabolized. NO activates soluble guanylyl cyclase in vascular endothelial cells, which increases the intracellular concentrations of cyclic GMP (cGMP). cGMP activates cGMP-dependent protein kinases, such as protein kinase G and I, which activates the downstream intracellular cascades. The downstream cascade results in reduced intracellular concentrations of calcium, caused by processes including inhibition of IP3-mediated pathway, phosphorylation of big calcium-activated potassium channel leading to cell hyperpolarization and reduced calcium influx, and increased calcium efflux via the Ca2+-ATPase-pump. Reduced intracellular calcium concentrations lead to the dephosphorylation of myosin light chains and the relaxation of smooth muscle cells.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6362
Submission : 1984-10-04
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-04-28
Pay. Date : 2013-12-24
DMF Number : 23216
Submission : 2009-10-21
Status : Active
Type : II
NDC Package Code : 42677-101
Start Marketing Date : 2011-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.6kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23217
Submission : 2009-10-21
Status : Active
Type : II
NDC Package Code : 42677-101
Start Marketing Date : 2011-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.6kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-01-22
Pay. Date : 2018-11-26
DMF Number : 29555
Submission : 2015-07-17
Status : Active
Type : II
NDC Package Code : 42677-101
Start Marketing Date : 2011-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.6kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-15
Pay. Date : 2012-12-24
DMF Number : 6778
Submission : 1987-01-09
Status : Active
Type : II
Certificate Number : R1-CEP 2007-261 - Rev 02
Issue Date : 2021-12-01
Type : Chemical
Substance Number : 1118
Status : Valid
Registration Number : 218MF10745
Registrant's Address : Via Bissone, 5, 20021-Baranzate, Milano, Italy
Initial Date of Registration : 2006-09-06
Latest Date of Registration : --
NDC Package Code : 46438-0025
Start Marketing Date : 2005-10-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2022-05-04
Registration Number : 20220504-209-J-1260
Manufacturer Name : Dipharma Francis Srl
Manufacturer Address : Via XXIV Maggio 40-33036 Mereto di Tomba (UD) Italy
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6789
Submission : 1987-01-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20816
Submission : 2007-08-24
Status : Inactive
Type : II
Certificate Number : R0-CEP 2020-153 - Rev 00
Issue Date : 2022-05-11
Type : Chemical
Substance Number : 1118
Status : Valid
NDC Package Code : 42677-101
Start Marketing Date : 2011-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.6kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21809
Submission : 2008-06-18
Status : Inactive
Type : II
Certificate Number : CEP 2008-112 - Rev 01
Issue Date : 2024-04-10
Type : Chemical
Substance Number : 1118
Status : Valid
Registration Number : 229MF10189
Registrant's Address : Keyuan Street, Shandong Shanghe Economic Development Zone, Jinan City, Shandong, China
Initial Date of Registration : 2017-10-26
Latest Date of Registration : --
Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2022-04-05
Registration Number : 20220324-209-J-1239(1)
Manufacturer Name : Shandong Keyuan Pharmaceutical Co., Ltd.
Manufacturer Address : Keyuan Street, Shandong Shanghe Economic Development Zone, Jinan, Shandong, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5607
Submission : 1984-11-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12679
Submission : 1997-10-02
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-15
Pay. Date : 2012-12-24
DMF Number : 6778
Submission : 1987-01-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6789
Submission : 1987-01-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6362
Submission : 1984-10-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-28
Pay. Date : 2013-12-24
DMF Number : 23216
Submission : 2009-10-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20816
Submission : 2007-08-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5607
Submission : 1984-11-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21809
Submission : 2008-06-18
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6777
Submission : 1987-01-09
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6803
Submission : 1987-02-05
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?